Anika Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $31.8M | $32.5M | $30.8M | $38.3M | $20.6M | $11.8M | $8.5M | $4.3M |
| Depreciation & Amortization | $4.3M | $3.7M | $3.8M | $4.7M | $4.8M | $4.5M | $4.0M | $3.3M |
| Depreciation | $3.3M | $2.7M | $2.7M | $2.6M | $2.7M | $2.5M | $1.8M | $1.3M |
| Amortization | $1.0M | $1.1M | $1.1M | $2.1M | $2.1M | $2.0M | $2.2M | — |
| Stock-Based Compensation | $5.8M | $3.4M | $2.2M | $1.6M | $1.3M | $1.2M | $1.2M | $1.1M |
| Net Cash from Operating Activities | $40.8M | $24.4M | $39.9M | $40.0M | $25.2M | $10.5M | $10.2M | $7.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $9.0M | $14.0M | $9.2M | $1.6M | $441.0K | $1.5M | $1.4M | $2.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-12.5M | $-6.8M | $-30.2M | $-8.3M | $-253.0K | $-1.5M | $-1.4M | $-2.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | $25.0M | — | — | — | — | — | — |
| Net Cash from Financing Activities | $314.0K | $-24.0M | $1.1M | $5.3M | $-5.7M | $-758.9K | $-1.2M | $-1.3M |
| Net Change in Cash | $29.0M | $-6.4M | $10.6M | $36.8M | $19.3M | $8.3M | $7.6M | $3.8M |
| Free Cash Flow | $31.8M | $10.4M | $30.7M | $38.4M | $24.7M | $9.0M | $8.8M | $5.1M |